Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

TNGX

Tango Therapeutics Inc

Apr 19 • 04:00PM ET

7.31

Dollar change -0.06
Percentage change -0.81	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN IBB SCHA LABU VTWO VHT IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.10	Insider Own	48.58%	Shs Outstand	102.20M	Perf Week	-0.68%
Market Cap	780.12M	Forward P/E	-	EPS next Y	-1.44	Insider Trans	-0.37%	Shs Float	54.88M	Perf Month	-14.00%
Income	-101.74M	PEG	-	EPS next Q	-0.31	Inst Own	52.43%	Short Float	18.57%	Perf Quarter	-33.12%
Sales	36.53M	P/S	21.36	EPS this Y	-19.33%	Inst Trans	-2.66%	Short Ratio	16.76	Perf Half Y	0.69%
Book/sh	2.48	P/B	2.95	EPS next Y	-11.40%	ROA	-23.44%	Short Interest	10.19M	Perf Year	101.93%
Cash/sh	3.16	P/C	2.31	EPS next 5Y	-	ROE	-40.49%	52W Range	2.47 - 13.03	Perf YTD	-26.16%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-35.09%	52W High	-43.90%	Beta	0.86
Dividend TTM	-	Quick Ratio	7.54	Sales past 5Y	132.62%	Gross Margin	88.51%	52W Low	195.95%	ATR (14)	0.45
Dividend Ex-Date	-	Current Ratio	7.54	EPS Y/Y TTM	10.85%	Oper. Margin	-312.57%	RSI (14)	33.24	Volatility	4.37% 5.55%
Employees	140	Debt/Eq	0.15	Sales Y/Y TTM	46.93%	Profit Margin	-278.54%	Recom	1.12	Target Price	17.57
Option/Short	Yes / Yes	LT Debt/Eq	0.15	EPS Q/Q	4.21%	Payout	-	Rel Volume	0.87	Prev Close	7.37
Sales Surprise	-34.12%	EPS Surprise	-16.79%	Sales Q/Q	-15.29%	Earnings	Mar 18 BMO	Avg Volume	607.92K	Price	7.31
SMA20	-3.61%	SMA50	-24.04%	SMA200	-13.32%	Trades		Volume	526,496	Change	-0.81%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-04-24	Initiated	Cantor Fitzgerald	Overweight
Feb-12-24	Initiated	Piper Sandler	Overweight	$18
Dec-08-23	Initiated	B. Riley Securities	Buy	$16
Oct-20-22	Upgrade	H.C. Wainwright	Neutral → Buy	$10
Sep-20-21	Initiated	SVB Leerink	Outperform	$25

Apr-01-24 04:48PM	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-20-24 05:31AM	Tango Therapeutics Inc (TNGX) Reports Full Year and Q4 2023 Financial Results (GuruFocus.com)
Mar-18-24 02:52PM	TNGX Stock Earnings: Tango Therapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) -7.09%
08:10AM	Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights (Business Wire)
05:20PM	Loading…
Mar-17-24 05:20PM	11 Oversold Biotech Stocks To Buy Right Now (Insider Monkey)
Mar-06-24 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (Business Wire)
Mar-05-24 04:47PM	Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire)
Feb-07-24 08:55AM	Pancreatic Cancer Treatments Poised for Major Advances in 2024 (PR Newswire)
Jan-31-24 07:00AM	Tango Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-05-24 04:05PM	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-04-24 02:47AM	Medivirs licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study (PR Newswire)
Jan-03-24 07:00AM	Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers (GlobeNewswire)
Nov-13-23 07:00AM	Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting (GlobeNewswire) -9.45%
Nov-08-23 03:12PM	Tango Therapeutics Inc (TNGX) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com)
07:00AM	Loading…
07:00AM	Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights (GlobeNewswire)
Nov-07-23 07:00AM	Tango Therapeutics to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-10-23 11:28AM	Tango Therapeutics (TNGX) Rises 20% in a Month: Here's Why (Zacks)
Oct-09-23 08:50AM	What Makes Tango Therapeutics, Inc. (TNGX) a Good Fit for 'Trend Investing' (Zacks) -13.27%
Sep-18-23 07:00AM	Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire) +5.88%
Sep-06-23 07:00AM	Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ Cancers (GlobeNewswire)
Sep-05-23 07:00AM	Tango Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-29-23 05:08PM	Tango Therapeutics Announces Updates to Its Board of Directors (GlobeNewswire)
Aug-28-23 07:00AM	Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer (GlobeNewswire)
Aug-10-23 07:00AM	Tango Therapeutics Announces $80 million Private Placement Financing (GlobeNewswire) -16.26%
Aug-07-23 07:00AM	Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Highlights (GlobeNewswire)
Jul-24-23 07:00AM	Tango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial in Patients With STK11-Mutant Cancers (GlobeNewswire)
Jul-10-23 07:00AM	Tango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial in Patients With MTAP-deleted Solid Tumors (GlobeNewswire)
Jun-01-23 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-09-23 07:00AM	Tango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights (GlobeNewswire) +6.40%
04:30PM	Loading…
Apr-18-23 04:30PM	Tango Therapeutics Presents Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting (GlobeNewswire) -11.67%
Apr-03-23 07:00AM	Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG260, a First-in-Class CoREST Inhibitor for the Treatment of STK11-Mutant Cancers (GlobeNewswire) +10.38%
Mar-27-23 07:00AM	Tango Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights (GlobeNewswire) -9.35%
Mar-14-23 08:11PM	Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting (GlobeNewswire)
Mar-10-23 10:15PM	Tango Therapeutics Announces Limited Exposure to Silicon Valley Bank (GlobeNewswire) -13.33%
Mar-06-23 07:00AM	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-01-23 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-28-23 07:00AM	Tango Therapeutics Announces Appointment of Adam Crystal, M.D., Ph.D. as President of Research and Development (GlobeNewswire) +6.09%
Feb-02-23 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-25-23 07:00AM	Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG462; Provides Additional Business Updates (GlobeNewswire)
Dec-15-22 07:00AM	HOOKIPA Pharma Appoints Katia Schlienger, M.D., Ph.D., Chief Medical Officer and Malte Peters, M.D., to Board of Directors (GlobeNewswire)
Nov-10-22 07:00AM	Tango Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Highlights (GlobeNewswire) -5.27%
Nov-07-22 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-19-22 07:00AM	Tango Therapeutics Announces Presentation of Preclinical Data on PRMT5 Inhibitors TNG908 and TNG462 in Three Abstracts Accepted at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-05-22 08:10AM	Tango Therapeutics Announces Presentation of Preclinical Data on TNG260 and Discovery Platform Advances at SITC 37th Annual Meeting (GlobeNewswire)
Sep-06-22 07:00AM	Tango Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) -12.62%
Aug-13-22 08:27AM	The Tango Therapeutics, Inc. (NASDAQ:TNGX) Second-Quarter Results Are Out And Analysts Have Published New Forecasts (Simply Wall St.)
Aug-10-22 07:00AM	Tango Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights (GlobeNewswire) +22.41%
Aug-02-22 07:00AM	Tango Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference (GlobeNewswire) +6.30%
Jun-27-22 07:00AM	Tango Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes (GlobeNewswire)
Jun-20-22 07:26AM	We Think Tango Therapeutics (NASDAQ:TNGX) Can Afford To Drive Business Growth (Simply Wall St.)
Jun-08-22 07:00AM	Tango Therapeutics to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference (GlobeNewswire)
May-11-22 07:00AM	Tango Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights (GlobeNewswire) -7.57%
May-09-22 07:00AM	Tango Therapeutics to Participate in the Guggenheim Synthetic Lethality Day 2022 (GlobeNewswire) -12.62%
Apr-19-22 07:22AM	Shareholders in Tango Therapeutics (NASDAQ:TNGX) are in the red if they invested a year ago (Simply Wall St.)
Mar-28-22 07:00AM	Tango Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights (GlobeNewswire)
Mar-08-22 04:57PM	Tango Therapeutics Announces Presentation of Preclinical Data on TNG908, USP1 Inhibitor Program and Discovery Platform in Three Abstracts Accepted at AACR 2022 Annual Meeting (GlobeNewswire)
Mar-03-22 09:41AM	Tango Therapeutics Announces Presentation of TNG908 Preclinical Combination Data at 2022 ESMO Targeted Anticancer Therapies Congress (GlobeNewswire) -7.42%
Feb-28-22 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-02-22 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-24-22 07:00AM	Tango Therapeutics Announces Clearance of TNG908 IND by FDA and Recent Pipeline Progress Updates (GlobeNewswire) +5.30%
Jan-11-22 09:37AM	We're Interested To See How Tango Therapeutics (NASDAQ:TNGX) Uses Its Cash Hoard To Grow (Simply Wall St.)
Dec-21-21 06:38PM	Boxer Capital, Llc Buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, ... (GuruFocus.com)
Nov-11-21 07:00AM	Tango Therapeutics to Participate in the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-10-21 10:42AM	Investors in Tango Therapeutics (NASDAQ:TNGX) have made a return of 24% over the past year (Simply Wall St.)
Nov-09-21 07:00AM	Tango Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights (GlobeNewswire)
Nov-01-21 07:00AM	Tango Therapeutics Announces Appointment of Dr. Marc Rudoltz as Chief Medical Officer and Doug Barry as General Counsel (GlobeNewswire)
Sep-30-21 04:31PM	Tango Therapeutics Announces Presentation of Preclinical Data on Lead Program and Discovery Platform in Five Abstracts Accepted at AACR-NCI-EORTC 2021 (Business Wire) +7.48%

Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin, Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Third Rock Ventures IV, L.P.	10% Owner	Feb 20 '24	Sale	12.00	162,500	1,950,000	19,201,475	Feb 21 05:52 PM
Weber Barbara	Chief Executive Officer	Feb 07 '24	Sale	12.62	4,457	56,246	1,535,167	Feb 08 09:14 PM
Crystal Adam	See Remarks	Feb 07 '24	Sale	12.62	4,083	51,527	119,478	Feb 08 09:04 PM
Beckman Daniella	Chief Financial Officer	Feb 07 '24	Sale	12.62	1,817	22,930	132,397	Feb 08 09:08 PM
Barry Douglas	General Counsel	Feb 07 '24	Sale	12.62	1,354	17,087	43,981	Feb 08 09:09 PM
Weber Barbara	Chief Executive Officer	Feb 06 '24	Sale	12.56	4,681	58,806	1,539,624	Feb 08 09:14 PM
Crystal Adam	See Remarks	Feb 06 '24	Sale	12.56	4,288	53,868	123,561	Feb 08 09:04 PM
Beckman Daniella	Chief Financial Officer	Feb 06 '24	Sale	12.56	1,908	23,969	134,214	Feb 08 09:08 PM
Barry Douglas	General Counsel	Feb 06 '24	Sale	12.56	1,422	17,864	45,335	Feb 08 09:09 PM
Crystal Adam	See Remarks	Nov 01 '23	Sale	8.39	7,507	62,994	81,250	Nov 02 04:49 PM
Boxer Capital, LLC		Oct 16 '23	Buy	6.84	500,000	3,420,000	8,198,642	Oct 17 06:04 PM
Boxer Capital, LLC		Oct 13 '23	Buy	7.07	750,000	5,302,500	7,698,642	Oct 17 06:04 PM
Boxer Capital, LLC		Oct 09 '23	Sale	9.97	175,000	1,744,750	6,948,642	Oct 11 09:22 PM
Boxer Capital, LLC		Oct 09 '23	Sale	9.91	50,000	495,500	693,524	Oct 11 09:22 PM
Boxer Capital, LLC		Aug 11 '23	Buy	5.15	475,000	2,446,250	743,542	Aug 15 09:34 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TNGX

Tango Therapeutics Inc

Upgrade your FINVIZ experience